Skip to Content

'
Jorge E. Romaguera

Present Title & Affiliation

Primary Appointment

Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1982 University of Puerto Rico, MD
1978 University of Puerto Rico, BS

Postgraduate Training

1/1988 Fellowship – Hematology (Lymphoma), University of Texas M.D. Anderson Cancer Center, Houston, TX
1/1987 Fellowship – Hematology/Oncology, University Hospital, San Juan
1/1985 Straight Internship – Internal Medicine, University Hospital, San Juan
1/1976 University of Puerto Rico
1/1976 Massachusetts Institute of Technology

Board Certifications

National Board of Medical Examiners
FLEX
American Board of Internal Medicine (Int.Med.)
American Board of Internal Medicine (Med.Oncol.)

Experience/Service

Academic Appointments

Associate Professor, Department of Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX, 9/1997-2005
Assistant Professor, Department of Hematology, Division Of Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX, 9/1993-8/1997
Faculty Associate, Department of Lymphoma, Division of Medicine, University of Texas M.D. Anderson Cancer Center,, Houston, TX, 10/1988-9/1993
Instructor, University of Texas Medical School, 8/1988-9/1988

Administrative Appointments/Responsibilities

Director, Quality Assurance Program, Houston, TX, 9/2009-present
Deputy Chairman, Lymphoma/Myeloma Department, Houston, TX, 9/2009-present
Member, Shared Resources Core Matching Committee, Partnership for Excellence in Cancer Research (UT MDACC and University of Puerto Rico), Houston, 2008-present
Physician Liaison, M.D. Anderson Cancer Center, Orlando, FL, 1/2003-present
Member, Continuity of Care Committee, Houston, TX, 2002-present
Telemedicine Program Lymphoma, MDACC Orlando, Orlando, FL, 1/1998-present

Other Appointments/Responsibilities

Alternate, CCMS (credentials committee), Houston, TX, 2007-present

Military or Other Governmental Service

Department Internal Medicine, Darnall Army Community Hospital, MEDDAC,, Active Duty - U.S. Army-Desert Shield/Desert Storm Operation, Fort Hood, Killeen, TX, 8/1990-5/1991
Major, Medical Corps, U.S. Army Reserve, 4005th USAH, Houston, TX, 10/1988-4/1994
Company B Rank, Captain, Medical Corps, Puerto Rico Army National Guard, 192nd Spt. Bn., 1/1986-9/1988

Institutional Committee Activities

Member, MDAPN Quality Management Committee, 1/2004-present
Member, Preceptorship Program for Physicians and Pharmacists, 1/1995-2004

Honors and Awards

2009 Eagle Award, Cancer Fighters of Houston
2006-2008 Nominee, Melvin L Samuels Award for Excellence in Patient Care, MDACC

Selected Publications

Peer-Reviewed Original Research Articles
1. Zhou Y, Wang H, Fang W, Romaguera J, Zhang Y, Delasalle K, Kwak LW, Yi Q, Du X, Wang M. Incidence trends of mantle cell lymphoma in the United States between 1975 and 2004. Cancer. In Press.
2. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu S, Banay R, Fayad L, Seveille W, Kwak L. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Journal of Clinical Oncology. In Press.
3. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B. Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. J Clin Oncol 27(23). e-Pub 7/2009. PMID: 19581539.
4. Garcia M, Romaguera JE, Inamdar KV, Rassidakis GZ, Medeiros LJ. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. Cancer 115(5):1041-8, 1/2009. PMID: 19170236.
5. Inamdar KV, Romaguera JE, Drakos E, Knobloch RJ, Garcia M, Leventaki V, Medeiros LJ, Rassidakis GZ. Expression of Eukaryotic Initiation Factor 4E Predicts Clinical Outcome in Patients with Mantle Cell Lymphoma Treated with Hyper-CVAD and Rituximab, Alternating with Rituximab, High-Dose Methotrexate, and Cytarabine. Cancer, 2009.
6. Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 113(10):2734-41, 11/2008. PMID: 18973182.
7. Shah JJ, Fayad L, Romaguera J. Mantle Cell International Prognostic Index (MIPI) Not Prognostic After R-HCVAD. Blood 112(6):2583, Sept 15 2008, 9/2008.
8. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 143(3):355-60, 9/2008. e-Pub 9/2008. PMID: 18764869.
9. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Lin P, Shi Y, Romaguera J, Kwak LW, Yi Q. A Severe Combined Immunodeficient-hu In vivo Mouse Model of Human Primary Mantle Cell Lymphoma. Clin Cancer Res 14(7):2154-2160, 4/2008. PMID: 18381957.
10. Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE, Kondo S, Younes A. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 36(4):443-50, 4/2008. PMID: 18343280.
11. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The additionof rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 19(3):553-9, 3/2008. PMID: 18083690.
12. Anderlini P; Saliba R; Acholonu S; Giralt SA; Andersson B; Ueno NT; Hosing C; Khouri IF; Coureil d; de Lima M; Qazilbash MH; Pro B; Romaguera J; Fayad L; Hagemeister F; Younes A; Munsell MF; champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 93(2):257-64, 2/2008. e-Pub 1/2008. PMID: 18223284.
13. Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. Am J Hematol 83(2):144-9, 2/2008. PMID: 17722077.
14. Oki Y; Pro B; Fayad LE; Romaguera J; Samaniego F; Hagemeister F; Neelapu S; McLaughlin P; Goy A; Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112(4):831-6, 2/2008. PMID: 18085611.
15. Wang, M; Han XH; Zhang L; Yang J; Qian JF; Shi YK; Kwak LW; Romaguera J; Yi Q. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 22(1):17-185, 1/2008.
16. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu S, Banay R, Fayad L, Seville W, Kwak L. Zevalin for orbital lymphoma paper. Journal of Clinical Oncology, 1/2008.
17. Romaguera JE. Mantle Cell Lymphoma: Frontline and Salvage Therapy. Current Hematologic Malignancy Reports 3(4):204-209, 2008.
18. Fayad L, Thomas D, Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma Suppl 2:S57-62, 12/2007. PMID: 18284717.
19. Soriano AO, Thompson MA, Admirand JH, Fayad LE, Rodriguez AM, Romaguera JE, Hagemeister FB, Pro B. Follicular Dendritic Cell Sarcoma: A Report of 14 Cases and a Review of the Literature. Am J Hematol 82(8):725-8, 8/2007. PMID: 17373675.
20. Iwuanyanwu E, Medeiros LJ, Romaguera J, Fayad LE. Mantle cell lymphoma with a rare involvement of the testicle. Leuk Lymphoma 48(6):1242-3, 6/2007. PMID: 17577795.
21. Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136(3):439-47, 2/2007.
22. Dang NH, Fayad L, McLaughlin P, Romaguera JE, Hagemeister FB, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin’s lymphoma. Br J Haematol 138:502-05, 2007.
23. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad II, Couch RB. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis 194(10):1394-7, 11/15/2006. e-Pub 10/6/2006. PMID: 17054068.
24. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad II, Couch RB. Dose Related Safety and Immunogenicity of Dose-Escalation Baculovirus-Expressed Trivalent Influenza Vaccine: A Double-blind, Control Trial in Adult Patients with Non-Hodgkin's B-Cell Lymphoma. J Infec Diseases 194(10):1394-97, November 15, 2006, 11/2006.
25. Younes A, Fayad L, Romaguera JE, Pro B, Goy A, Wang M,. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 42(17):2976-81, 11/2006. e-Pub 9/27/2006. PMID: 17008093.
26. Wedgwood A, Medeiros LJ, Romaguera JE. CD20+ nodal marginal zone B-cell lymphoma with CD20-recurrence as an intracranial dural-based mass. Leuk Lymphoma 47(10):2253-6, 10/2006. PMID: 17071504.
27. Pro B, Hagemeister FB, McLaughlin P, Romaguera JE, Rodriguez MA, Cabanillas F, Tiongson LP, Younes. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin’s lymphoma. Leuk Lymphoma 47(9):1818-21, 9/2006.
28. Safdar A, Gillenwater AM, Jones DM, Jorgensen JL, Romaguera JE,. Rosai-Dorfman disease misdiagnosed as active tuberculosis. Leuk Lymphoma 47(7):1441-42, 7/2006.
29. Wang M, Zhou Y, Zhang L, Nguyen CA, Romaguera J. Use of bortezomib in B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 6(7):983-91, 7/2006. PMID: 16831071.
30. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24(10):1582-9, 4/2006. PMID: 16575009.
31. Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 47(3):481-5, 3/2006. PMID: 16396772.
32. Wedgwood A, Medeiros LJ, Romaguera JE. CD20 plus nodal marginal zone B-cell lymphoma with CD20-recurrence as an intracranial dural-based mass. Leuk Lymphoma 47:2253-56, 2006.
33. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23(28):7013-23, 10/2005. e-Pub 9/6/2005. PMID: 16145068.
34. Ha CS, Cabanillas F, Lee MS, Tucker SL, McLaughlin P, Rodriguez MA, Younes A, Romaguera JE, Mesina OM, Cox JD. A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma. Int J Radiat Oncol Biol Phys 63(1):188-93, 9/2005. PMID: 16111588.
35. Tsimberidou AM, Younes A, Romaguera J, Hagemeister FB, Rodriguez MA, Feng L, Ayala A, Smith TL, Cabanillas F, McLaughlin P. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer 104(2):345-53, 7/2005. PMID: 15948158.
36. McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A, Hayes K, Maddox AM, Preti HA, Hagemeister FB. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 105(12):4573-5, 6/2005. e-Pub 3/1/2005. PMCID: PMC1895007.
37. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35:943-51, 5/2005. PMID: 15806128.
38. Caraway NP, Gu J, Lin P, Romaguera JE, Glassman A, Katz R. The utility of interphase fluorescence in situ hybridization for the detection of the translocation t(11;14)(q13;q32) in the diagnosis of mantle cell lymphoma on fine-needle aspiration specimens. Cancer 105(2):110-8, 4/2005. PMID: 15712276.
39. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23(4):667-75, 2/2005. e-Pub 12/21/2004. PMID: 15613697.
40. Romaguera JE, Hagemeister FB. Lymphoma of the colon. Curr Opin Gastroenterol 21:80-84, 2005.
41. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22(20):4095-102, 10/2004. e-Pub 9/7/2004. PMID: 15353540.
42. Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, Dang NH, Fiumara P, Loyer EM, Cabanillas FF, McLaughlin PW, Rodriguez MA, Samaniego F. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 10(16):5432-8, 8/2004. PMID: 15328181.
43. Gu J, Huh YO, Jiang F, Caraway NP, Romaguera JE, Zaidi TM, Fernandez RL, Zhang H, Khouri IF, Katz RL. Evaluation of peripheral blood involvement of mantle cell lymphoma by fluorescence in situ hybridization in comparison with immunophenotypic and morphologic findings. Mod Pathol 17(5):553-60, 5/2004. PMID: 15001994.
44. Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 33:1015-23, 5/2004. PMID: 15048145.
45. Pro B, Younes A, Albitar M, Dang NH, Samaniego F, Romaguera J, McLaughlin P, Hagemeister FB, Rodriguez MA, Clemons M, Cabanillas F. Thalidomide for patients with recurrent lymphoma. Cancer 100(6):1186-9, 3/2004. PMID: 15022285.
46. Tsimberidou AM, Giles F, Romaguera J, Duvic M, Kurzrock R. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer 100(3):574-80, 2/2004. PMID: 14745875.
47. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning JT, Jr, Jones D, Abruzzo LV, Medeiros LJ. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 98(2):310-4, 7/2003. PMID: 12872350.
48. Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, Younes A, McLaughlin P, Goy A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97(3):586-91, 2/2003. PMID: 12548600.
49. Wilder RB, Romaguera JE, Tucker SL, Ha CS, Hess MA, Cabanillas F, Cox JD. Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma. Cancer 94(3):601-5, 2/2002. PMID: 11857290.

Invited Articles
1. Romaguera J, Hagemeister FB. Lymphoma of the colon. Curr Opin Gastroenterol 21(1):80-4, 2005. PMID: 15687889.
2. Romaguera JE. Mantle Cell Lymphoma. Hematologia, Citocinas, Immunoterapia y Terapia Celular., 7/2003.

Abstracts
1. Samaniego F, Fanale M, Pro B, Hagemeister FB, McLaughlin P, Romaguera JE, Neelapu S, Rodriguez A, Fayad L, Younes A, Kwak L. Pentostatin, cyclophosphamide, and rituximab (PCR) achieve high response rates in indolent B-cell lymphoma without prolonged myelosuppression. Blood 112:835, 11/2008.
2. Romaguera JE, Fayad L, McLaughlin P, Pro B, Rodriguez MA, Wang M, Weaver P, Hartig K, Kwak L, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I trial of bortezomib in combination with rituximab-hyperCVAD/methotrexate and cytarabine for untreated mantle cell lymphoma. Blood 112:3051, 11/2008.
3. Romaguera J, Fayad L, Rodriguez A, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Shah J, Weaver P, Hartig K, Cabanillas F, Kwak L, Kantarjian H, Wang M. Rituximab (R) + hypercvad alternating with R-Methotrexate/Cytarabine after 9 years: Continued high rate of failure-free survival in untreated mantle cell lymphoma (MCL). Blood 112:833, 11/2008.
4. Romaguera J, Coiffier B, Crump M, Herbrecht R, Verhoef G, Hanushevsky O, Strahs A, Hewes B, Berkenblit A, Hess G. Supportive efficacy analyses for the phase III study of temsirolimus versus investigator's choice therapy for the treatment of patients with relapsed or refractory mantle cell lymphoma. Blood 112:1559, 11/2008.
5. Romaguera JE. Mantle Cell Lymphoma: Frontline and Salvage Therapy. Current Hematologic Malignancy Reports 3(4):204-209, 10/2008.
6. Romaguera JE, Wang M. Lenalidomide in combination with rituximab demonstrated early evidence of efficacy in a phase I/II study in relapsed/refractory Mantle Cell Lymphoma, 2008 Mantle Cell Lymphoma Workshop, Dallas, Texas, 3/2008.
7. Wang M, Zhang L, Fayad L, Hagemeister FB, Neelapu S, Samaniego F, Pro B, Younes A, Miller S, Knight RD, Zeldis JB, Yi Q, Romaguera JE. Lenalidomide and rituximab are a promising combination in vitro, in vivo preclinically and in a phase I/II clinical trial in relapsed/refractory mantle cell lymphoma. Blood 112:3058, 2008.
8. Romaguera JE, Pro B, Fayad L, McLaughlin P, Wang M, Weaver P, Hartig K, Hagemeister F, Rodriguez MA, Younes A, Samaniego F, Fanale M, Kwak L, Feldman T, Goy A. Phase I trial of bortezomib in combination with rituximab-hypercvad/methotrexate and cytarabine for untreated mantle cell lymphoma. Annals of Oncology 19(4):iv214 (#444), 2008.
9. Wedgwood A, Fanale M, Fayad L, McLaughlin P, Hagemeister F, Pro B, Romaguera J, Rodriguez MA, Samaniego F, Younes A. Rituximab + ABVD improves event-free survival (EFS) in patients with classical hodgkin lymphoma in all international prognostic score (IPS) groups and in patients who have PET positive disease after 2-3 cycles of therapy. Blood 110 (#215), 2008.
10. Michael Wang, Yuankai Shi, Liang Zhang, Xiaohong Han, Jing Yang, Jianfei Qian, Sungyoul Hong, Pei Lin, Jorge Romaguera, Larry W. Kwak, and Qing Yi. A SCID-hu In Vivo Mouse Model of Human Primary Mantle Cell Lymphoma. Blood 110(11):691a, 11/2007.
11. Liang Zhang, Yuankai Shi, Xiaohong Han, Jing Yang, Jianfei Qian, Larry W. Kwak, Jorge Romaguera, Qing Yi, and Michael Wang. Bortezomib Is Synergistic with Rituximab and Cyclophosphamide in Inducing Apoptosis of Mantle Cell Lymphoma Cells In Vitro and In Vivo. Blood 110(11):200B, 11/2007.
12. Michael A. Thompson, Tapan M. Kadia, B. Nebiyou Bekele, Michael Wang, and Jorge E. Romaguera. Cyclin D1 Polymorphisms as Predictive and Prognostic Molecular Markers in 90 Mantle Cell Lymphoma Patients Treated with R-HyperCVAD. Blood 110(11):472a, 11/2007.
13. Wang M, Fayad L, Hagemeister F, Neelapu S, Samuels B, Samanigo F, Pro B, Yi Q, Bell N, Byrne C, Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera J. Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL). Blood 110(11):755a, 11/2007.
14. Maria Alma Rodriguez, Michelle Fanale, Fredrick Hagemeister, Peter McLaughlin, Barbara Pro, Jorge Romaguera, Larry Kwak, Luis Fayad, Xuelin Huang, and Jean Bernard Durand. Phase II Study of RCHOP with Pegylated Liposomal Doxorubicin (DRCOP) for Patients > 60 Years Old with Untreated Diffuse Large B Cell Lymphoma (DLBCL). Blood 110(11):187B, 11/2007.
15. Barbara Pro, Luis Fayad, Jorge Romaguera, Michelle Fanale, Anas Younes, Fredrick B. Hagemeister, Felipe Samaniego, Peter McLaughlin, M.A. Rodriguez, Larry Kwak, and Nam H. Dang. Preliminary Results of a Phase II Study of HCVIDDoxil Alternated with Methotrexate-Cytarabine in Patients with Newly Diagnosed T-Cell Lymphoma. Blood 110(11):1013A, 11/2007.
16. Luis Fayad, Barbara Pro, Fredrick Hagemeister, Fernando Cabanillas, Felipe Samaniego, Peter McLaughlin, Michael Wang, Sattva Neelapu, Larry Kwak, Jorge Romaguera, and Maria A. Rodriguez. R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years. Blood 110(11):387a, 11/2007.
17. Amanda R. Wedgwood, Michelle A. Fanale, Luis E. Fayad, Peter McLaughlin, Fredrick B. Hagemeister, Barbara Pro, Jorge Romaguera, Maria A. Rodriguez, Felipe Samaniego, and Anas Younes. Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2–3 Cycles of Therapy. Blood 110(11):71a, 11/2007.
18. Michael J. Overman, Lei Feng, Barbara Pro, Peter McLaughlin, Mark Hess, Felipe Samaniego, Anas Younes, Jorge E. Romaguera, Frederick B. Hagemeister, Larry Kwak, Fernando Cabanillas, Maria A. Rodriguez, and Luis E. Fayad. The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone. Blood 110(11):388a, 11/2007.
19. Yuhong Zhou, Haijun Wang, Xin Du, Qing Yi, Yanxia Zhang, Jorge Romaguera, and Michael Wang. Trend and Geographic Variations in the Incidence of Mantle Cell Lymphoma in the United States over 30 Years from 1975 to 2004. Blood 110(11):172B, 11/2007.
20. Wang M, Fayad L, Hagemeister F, Neelapu S, Bell N, Byrne C, Knight R, Zeldis J, Kwak L, Romaguera J. A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S), 6/2007.
21. Michael Wang, Liang Zhang, Xiaohong Han, Jing Yang, Jianfei Qian, Sungyoul Hong, Felipe Samaniego, Jorge Romaguera, and Qing Yi. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood 109(12):5455-5462, 6/2007. e-Pub 2/22/2007. PMID: 17317853.
22. A. Huen, J. E. Romaguera, L. E. Fayad, S. R. Teegala, Y. Ji, S. Vadhan-Raj. Increased toxicity associated with delayed clearance of methothrexate (MTX) in patients with lymphoma receiving high-dose MTX. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25(18S), 6/2007.
23. M. A. Rodriguez, S. Temple, L. Fayad, F. Hagemeister, P. McLaughlin, J. Romaguera, F. Cabanillas. Predictive value for survival of a risk model of two serological markers, beta-2-microglobulin (B2M) and lactic dehydrogenase (LDH), in diffuse large cell lymphoma (DLCL). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25(18S), 6/2007.
24. L. Fayad, S. Temple, B. Pro, F. Hagemeister, F. Cabanillas, F. Samaiego, P. McLaughlin, M. Wang, L. Kwak, J. Romaguera, M. A. Rodriguez. R-HCVAD/R-MTX-ARAC is an effective regimen for untreated diffuse large B-cell lymphoma (DLBCL) with aggressive features: M. D. Anderson experience in 40 patients. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25(18S), 6/2007.
25. S. R. Teegala, X. Zhou, A. Huen, Y. Ji, L. E. Fayad, J. E. Romaguera, S. Vadhan-Raj. Risk factors for neutropenic fever in lymphoma patients receiving chemotherapy. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25(18S), 6/2007.
26. X. Zhou, S. R. Teegala, A. Huen, Y. Ji, L. E. Fayad, J. E. Romaguera, F. B. Hagemeister, S. Vadhan-Raj. Risk factors for severe anemia requiring red blood cell transfusions in lymphoma patients receiving chemotherapy. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25(18S), 6/2007.
27. Y. Zhou, H. Wang, Y. Zhang, X. Du, L. Kwak, J. Romaguera, M. Wang. Trend and geographic variations in the incidence of mantle cell lymphoma in the United States from 1975 to 2003. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25(18S), 6/2007.
28. Pro B, Nunez RF, Romaguera J, Rodriguez MA, Hagemeister FB, Fayad L. Achievement of FDG-PET Negativity Does Not Predict Durable Responses in T-Cell Lymphoma. Blood 108 (#2404), 11/2006.
29. Wang M, Zhang L, Han X, Yang J, Qian J, Wang S, Hong S, Zhang X, Zhou Y, Romaguera JE, Yi K. Atiprimod Inhibits Growth of Mantle Cell Lymphoma In Vitro and In Vivo and Induces Apoptosis Via Activation of the Mitochondrial Pathway. Blood 108 (#2514), 11/2006.
30. Romaguera JE, Fayad L, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang L, Kantarjian HM, Beasley V, Medeiros LJ, Katz RL, Cabanillas F. Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A). Blood 108 (#2749), 11/2006.
31. Fayad L, Overman M, Pro B, McLaughlin P, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Rodriguez MA. Favorable Results of Rituximab in Combination with CHOP in the Front-Line Treatment of Follicular Lymphoma Grade 3. Blood 108 (#2770), 11/2006.
32. Teegala S, Zhou X, Huen A, Ji Y, Fayad L, Romaguera JE, Hagemeister FB, Vadhan-Raj S. High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors. Blood 108 (#4103), 11/2006.
33. Huen A, Zhou X, Teegala S, Ji Y, Fayad L, Romaguera JE, Hagemeister FB, Vadhan-Raj S. Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy. Blood 108 (#3994), 11/2006.
34. Fayad L, Liebmann J, Modiano M, Cohen G, Pro B, Romaguera JE, Stromatt S. Results of a Phase I/II Trial of Pixantrone in Combination with Fludarabine, Dexamethasone, and Rituximab in the Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL). Blood 108 (#2758), 11/2006.
35. Younes A, Fayad L, Goy A, McLaughlin P, Pro B, Romaguera JE, Hagemeister FB, Rodriguez MA, Samaniego F, Kwak L, Neelapu S, Medeiros LJ, Wedgwood A, Fanale M. Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups. Blood 108 (#2714), 11/2006.
36. Younes A, Rodriguez M, Pro B, McLaughlin P, Romaguera JE, Hagemeister F, Wang M. A phase II study of Yttrium 90 (90Y) Ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). . Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland Ann Oncol:Suppl 5 (#201), 2005.
37. Dang J, Pro B, Romaguera JE, Fayad L. Gallium Scan after the second and fourth chemotherapy cycle predicts clinical outcomes in aggressive non-Hodgkin’s lymphomas. J Clin Oncol 23:578s (#6576), 2005.
38. Romaguera J, Fayad L, Rodriguez M, Hagemeister F, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris A, Dang N, Medeiros L, Katz R, Gagneja H, Samuels B, Cabanillas F. High rates of failure-free survival (FFS) and overall sirvival (OS) in untreated mantle cell lymphoma (MCL) after rituximab plus hyperCVAD (R-HCVAD) alternating with rituximab plus high-dose methotrexate-cytarabine (R-M/A). Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland. Ann Oncol 16:v94 (#197), 2005.
39. Younes A, McLaughlin P, Romaguera J, Hagemeister F, Pro B, Dang N, Samaniego F, Rodriguez M, Fayad L. Paclitaxel plus topotecan plus rituximab (TTR): An effective salvage program for the treatment of patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL). Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland. Ann Oncol 16:v101 (#220), 2005.
40. Jabbour E, Hosing C, Pro B, Champlin J, Khouri I, Romaguera JE, Fayad LE. Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin’s lymphoma (HL). . J Clin Oncol 23:562s (#6509), 2005.
41. Fayad L, Romaguera J, Hart S, Younes A, Pro B, Hagemeister F, McLaughlin P, Dang N, Preti A, Sarris A, Gil F. Report of a phase II study of sphingosomal vincristine (SV) in patients with relapsed or refractory Hodgkin’s disease. Proceeding of American Society of Clinical Oncology 23:591s (#6624), 2005.
42. Younes A, McLaughlin P, Fayad L, Goy A, Medeiros L, Pro B, Romaguera J, Rodriguez M, Samaniego F, Dang N. Rituximab plus ABVD therapy for newly diagnosed patients with classical Hodgkin lymphoma: A novel combination program targeting the cancer cells and the reactive B-cells in the microenvironment. Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland. Ann Oncol 16:v196 (#545), 2005.
43. McLaughlin P, Liu N, Poindexter N, Grimm E, Fayad L, Hagemeister F, Nunez R, Romaguera J, Goy A, Samaniego F, Wang M, Ayala A, Lee B, Reuben J, Kwak L, Rodriguez M. Rituximab plus GM-CSF (Leukine) for indolent lymphoma. Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland (oral). Ann Oncol 16:v68 (#104), 2005.
44. McLaughlin P, Rodriguez M, Hagemeister F, Romaguera J, Sarris A, Younes A, Dang N, Goy A, Samaniego F, Hess M, Lee M, Medeiros L, Fayad L, Pro B, Jiang Y, Ayala A, Cabanillas F. Stage IV indolent lymphoma: A randomized trial of concurrent vs sequential FND (Fludarabine, Mitoxantrone, Dexamethasone) and rituximab with interferon maintenance. Proceedings of the 9th International Conference on Malignant Lymphomas. Lugano, Switzerland. Ann Oncol 16:100 (#247), 2005.
45. Oki Y, Pro B, Delpassand E, Ballaster V, McLaughlin P, Romaguera JE, Wang M, Hagemeister FB, Younes A. A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL). . Blood 104:720a (#2632), 11/2004.
46. Dang N, Pro B, Hagemeister FB, Jones D, Samuels B, Rodriguez MA, Goy A, Romaguera JE, Walker P, Kwak L, Fayad L. Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma. Blood 104:722a (#2641), 11/2004.
47. Younes A, Fayad L, Romaguera JE, Pro B, Goy A, Dang N, Wang M. Long-Term Safety and Efficacy of Single Administration of a Fixed Dose Pegfilgrastin (Neulasta) in Inducing Neutrophil Count Recovery after ABVD Chemotherapy in Patients with Hodgkin Lymphoma. . Blood 104:245b (#4646), 11/2004.
48. McLaughlin P, Estey E, Glassman A, Romaguera JE, Samaniego F, Ayala A, Hayes K, Maddox A, Preti H, Hagemeister FB. Myelodysplasia and Acute Myeloid Leukemia Folllowing Therapy for Indolent Lymphoma with Fludarabine, Mitoxantrone, Dexamethasone (FND) Plus Rituximab and Interferon Alfa. Blood 104:391a-392a (#1394), 11/2004.
49. Fayad L, Liebmann J, Modiano M, Cohen G, Pro B, Romaguera JE, Davite C, Lymboura M, Comis S, Laffranchi B. Preliminary Results of Phase I/II Trial of BBR-2778 (Pixantrone) in Combination with Fludarabine, Dexamethasone, and Rituximab (FPD-R) in the Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL). Blood 104:373a (#1324), 11/2004.
50. Younes A, Pro B, Romaguera JE, Dang N. Safety and Efficacy of Bortezomib (Velcade) for the Treatment of Relapsed Classical Hodgkin’s Disease. Blood 104:722a (#2638), 11/2004.
51. Rodriguez M, Sarris A, Dang N, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Samaniego F, Younes A, Cabanillas F. Sphingosomal Vincristine in CHOP +/- Rituximab Is a Promising New Treatment for Patients with High Risk Untreated Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results of a Phase II Study. Blood 104:234b (#4602), 11/2004.
52. Sarma A, Rodriguez MA, Cabanillas F, Dang NH, McLaughlin P, Hagemeister FB, Pro B, Romaguera JE, Younes A, Grimm EA. A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma. American Society of Clinical Oncology (ASCO) 22:745s, 2004.
53. Sarma A, Rodriguez MA, Cabanillas F, Dang NH, McLaughlin P, Hagemeister FB, Pro B, Romaguera J, Younes A, Grimm EA. A Randomized trial of CHOP chemotherapy with or without melatonin In patients with favorable prognosis large B-cell lymphoma. J Clin Oncol 22(14S):745s, 2004.
54. Romaguera JE, Fayad L, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris A, Dang N, Medeiros L, Katz R, Gagneja H, Samuels B, Cabanillas F. Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS). Blood 104:40a (#128), 2004.
55. Rodriguez MA, Dang NH, Fayad LE, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Youens A, Cabanillas F. Sphingosomal vincristine in CHOP in a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin’s lymphoma. . American Society of Clinical Oncology (ASCO) 22:748s, 2004.
56. Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera J, Younes A, Cabanillas F. Sphingosomal vincristine in CHOP is a promising new treatment for Elderly, as well as for poor prognosis patients with aggressive Non-Hodgkins lymphoma (NHL): follow-up results of a phase II study. J Clin Oncol 22(14S):748s, 2004.
57. Goy A, Younes A, McLaughlin P, Pro B, Romaguera J, Hagemeister FB, Fayad L, Trehu EG, Schenkein D, Rodriguez MA. Update on a phase 2 study of bortezomib in patient (pts) with relapsed or refractory indolent or aggressive non-Hodgkin’s lymphomas (NHL). J Clin Oncol 22(14S):577s, 2004.
58. Romaguera J, Cabanillas F, Dang N, Goy A, Fayad L, Hagemeister FB, McLaughlin P, Pro B, Rodriguez MA, Samaniego F, Sarris A, Younes A, Medeiros J, Gagneja GH. Mantle Cell Lymphoma (MCL) – Update on Results After R-HCVAD Without Stem CellTransplant (SCT). . Annals of Oncology 13(2):8, 2002.

Book Chapters
1. Romaguera JE, McLaughlin P. Mantle Cell Lymphoma, Chapter 102. In: Williams Hematology, 8th Edition. Ed(s) Kaushansky, Lichtman, Butler, Kipps, Seligsohn, Pechal. McGraw-Hill: Burr Ridge, Illinois. In Press.
2. Frederick WAI, Romaguera JE, Reilly JA, and Grau AM. “Hematologic Malignancies and Splenic Tumors”. In: M.D. Anderson Surgical Oncology Handbook, Fourth Edition. A Lippincott Williams & Wilkins: Philadelphia PA., 464-479, 2006.
3. Frederick WAI, Romaguera JE, Reilly JA, Grau AM. Hematologic Malignancies and Splenic Tumors. In: M.D. Anderson Surgical Oncology Handbook, Third Edition. Lippincott Williams and Wilkins, 2003.

Letters to the Editor
1. Safdar A, Gillenwater AM, Jones DM, Jorgensen JL, Romaguera JE. Rosai-Dorfman disease misdiagnosed as active tuberculosis. Leuk Lymphoma 47(7):1441-2, 7/2006. PMID: 16923590.

Manuals, Teaching Aids, Other Teaching Publications
1. Romaguera JE, Koeller C. Hematology Course: MDACC, 2008.
2. Romaguera JE. American Society of Hematology (ASH) Teaching Cases – Lymphodemopathy; ASH Case Bank, 2006.
3. Romaguera JE, Huen A. Non-Hodgkin’s Lymphoma Section. Color-Matrix Cancer Staging and Treatment Handbook. Third Edition., 2004.
4. Romaguera JE, Huen A. Non-Hodgkin’s Lymphoma Section. Color-Matrix Cancer Staging and Treatment Handbook. Second edition., 2003.

Grant & Contract Support

Title: Phase II study of bortezomib (VELCADE) plus rituximab-hyperCVAD alternating with bortezomib plus rituximab-high dose methotrexate/cytarabine in patients with untreated aggressive mantle cell lymphoma
Funding Source: Millenium
Role: Principal Investigator
Duration: 8/31/2009 - present

Last updated: 9/18/2009